冠忠巴士集團(00306.HK)中期淨虧損9561.2萬港元 同比擴大28.32%
格隆匯11月29日丨冠忠巴士集團(00306.HK)公佈,截至2021年9月30日止6個月,公司實現收入5.35億港元,同比增加12.24%;公司擁有人應占虧損9561.2萬港元,同比擴大28.32%;每股虧損20.05港仙。
公司全資附屬公司環島中港通旅運有限公司為香港領先的非專利跨境巴士服務營運商。跨境非專利巴士業務的收入減少,主要是由於政府所實施的防疫措施包括嚴格控制旅客管制站,導致出入境活動自2020年年初起陷入空前停滯。
集團將保持審慎樂觀的態度,密切注視市場發展,並將維持其審慎而迅敏的業務策略。集團將繼續悉力克服目前困境,為各持份者維持可持續的價值。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.